{"id":"cyclosporine-a-0-05-eye-drop","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation / burning sensation"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Foreign body sensation"},{"rate":null,"effect":"Transient blurred vision"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cyclosporine A is a calcineurin inhibitor that blocks T-cell receptor signaling and prevents the transcription of pro-inflammatory cytokines such as IL-2, TNF-α, and IFN-γ. In the eye, this immunosuppressive action reduces the inflammatory cascade responsible for dry eye disease and other ocular surface disorders. The 0.05% ophthalmic formulation delivers the drug topically to maximize local effect while minimizing systemic exposure.","oneSentence":"Cyclosporine A suppresses T-cell activation and reduces inflammatory cytokine production in the eye, thereby decreasing ocular surface inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:25.581Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Dry eye disease (keratoconjunctivitis sicca)"},{"name":"Ocular surface inflammation"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["NOVA22007"],"phase":"phase_3","status":"active","brandName":"Cyclosporine A 0,05% eye drop","genericName":"Cyclosporine A 0,05% eye drop","companyName":"Campus Bio-Medico University","companyId":"campus-bio-medico-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cyclosporine A suppresses T-cell activation and reduces inflammatory cytokine production in the eye, thereby decreasing ocular surface inflammation. Used for Dry eye disease (keratoconjunctivitis sicca), Ocular surface inflammation.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}